STING agonist-loaded cationic radioactive microspheres enhance transarterial radioembolization of hepatocellular carcinoma via tumor immune activation

T cell response and enhances the tumor immune microenvironment, resulting in significant therapeutic efficacy against HCC. This approach effectively overcomes the current limitations of poor embolic efficacy and non-target embolization associated with radioactive microspheres. Moreover, it activates the tumor immune microenvironment, addressing the issue of tumor immune resistance and further improving therapeutic outcomes, thereby showing great clinical application potential.